According to the law firm press release, Perrigo Company plc is a manufacturer of generic drugs and over-the-counter healthcare products.

On April 8, 2015, competing drug manufacturer Mylan approached the Perrigo Board of Directors with an offer to purchase Perrigo for $205 per share, representing a nearly 30% premium to the Company's total market capitalization. Mylan's approach was well received by investors, and the price of Perrigo stock increased to as high as $215 per share in intraday trading on April 8.

However, beginning on April 21, 2015, and continuing throughout the Class Period, Perrigo publicly rejected Mylan's offer and falsely told investors that the offer substantially undervalued Perrigo and its growth prospects, and that the offer did not take into account the full benefits of the Company's acquisition of Omega Pharma N.V. ("Omega"). Even though Mylan subsequently raised its offer to approximately $235 per share, over the next six months, Perrigo continued to engage in a public campaign to convince shareholders to reject Mylan's proposal. Convinced by Perrigo's strong opposition to Mylan's tender offer, on November 13, 2015, the majority of the Company's shareholders declined to tender their shares making the tender offer a failure. Moreover, Defendants' misrepresentations caused Perrigo shares to trade at artificially inflated prices throughout the Class Period.

The truth began to be revealed on February 18, 2016, when Perrigo reported fourth quarter 2015 revenue, margins, earnings, and cash flow that were all lower than investors had been led to expect, and decreased earnings guidance for 2016. The Company also announced the sudden need to restructure parts of the Omega business, and that it would need to take a $185 million impairment charge related to Omega's assets. Then, on April 22, 2016, Reuters reported that Perrigo's longtime CEO would be appointed as the new CEO of competing pharmaceutical company Valeant Pharmaceuticals. Days later, on April 25, 2016, Perrigo confirmed that the CEO was, in fact, resigning to become the new CEO of Valeant. The Company also drastically lowered its earnings guidance for 2016 and announced weak preliminary first-quarter 2016 results. The Company attributed its poor financial performance to increased competitive pressures and weaker than expected performance within Omega. Then, on May 12, 2016, Perrigo announced a first quarter net loss of $0.93 per share (which the Company later revised to a loss of $2.34 per share), which the Company largely attributed to an additional $467 million impairment charge relating to the Omega acquisition. These disclosures caused a material decline in the price of Perrigo stock.

On February 10, 2017, the Court issued an Order appointing Lead Plaintiff and Counsel. Lead Plaintiff filed an amended Complaint on June 21, 2017. Defendants filed Motions to Dismiss on August 21. On July 27, 2018, the Court issued an Order granting in part and denying in part Defendants' Motions to Dismiss, dismissing some of the individual Defendants.

On April 9, 2021, Defendants filed a Motion for Summary Judgment. On August 17, 2023, the Court issued an Order granting in part and denying in part the Motion for Summary Judgment.

On April 4, 2024, the parties entered into a Stipulation and Agreement of Settlement. The Court granted preliminary approval of the Settlement on April 23.